VBWG
Meeting report

HOPE-2 trial

HOPE-2 results: No CV benefit from homocysteine lowering with folic acid plus B vitamins in high-risk patients




HOPE-2

Download VBWG06_HOPE-2.ppt (12 slides - 0.7MB)

HOPE-2 HOPE-2: Rationale HOPE-2: Study design HOPE-2: Baseline characteristics HOPE-2: Baseline prevalence of CV risk factors HOPE-2: Baseline prevalence of CVD HOPE-2: Baseline medication use HOPE-2: Change in plasma homocysteine over time HOPE-2: Primary outcome shows no benefit of vitamin supplementation HOPE-2: Primary outcome and components HOPE-2: Secondary outcome and components HOPE-2: Summary



folichomocysteinevitamins